What is the recommended treatment for proctitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment of Proctitis

For ulcerative proctitis, start with rectal 5-ASA suppositories 1 g daily as first-line therapy; for sexually transmitted proctitis, use ceftriaxone 125 mg IM plus doxycycline 100 mg twice daily for 7 days. The treatment approach fundamentally depends on whether you're dealing with inflammatory bowel disease-related proctitis or infectious/sexually transmitted proctitis.

Ulcerative Proctitis (IBD-Related)

First-Line Treatment

  • Rectal 5-ASA suppository 1 g once daily (typically at night) 1
  • This is a strong recommendation based on high-quality evidence showing superiority over placebo with pooled odds ratios of 8.30 for symptomatic remission and 5.31 for endoscopic remission 1
  • Rectal 5-ASA is also superior to rectal corticosteroids for inducing remission (OR 1.65) 1

If Incomplete Response After 4-8 Weeks

Add oral 5-ASA 2-3 g daily to the rectal suppository 1, 2

  • Evaluate response within 4-8 weeks 1
  • The combination of rectal and oral therapy is more effective than oral alone for disease beyond proctitis 1

Second-Line Options for Refractory Disease

If still no response:

  1. Switch to or add corticosteroid suppository (e.g., prednisolone 5 mg) while continuing oral 5-ASA optimized to 4-4.8 g daily 2
  2. If this fails: Oral prednisolone 40 mg once daily, weaning over 6-8 weeks 2, 1

Third-Line for Truly Refractory Proctitis

When conventional therapy fails (approximately 30% of patients develop refractory disease 3):

  • Anti-TNF therapy (infliximab, adalimumab, or golimumab) 4, 5
  • Topical tacrolimus 4, 5
  • Anti-integrin therapy (vedolizumab) - recent real-world data shows this may have the highest treatment persistence and response rates in isolated proctitis 6
  • JAK inhibitors or S1P agonists 7

Important caveat: Nearly 30% of patients with ulcerative proctitis will develop refractory disease, and approximately 51% may experience proximal disease extension 3, 8. Monitor closely with endoscopy at 3-6 months after treatment initiation 9.

Maintenance Therapy

Once remission is achieved, continue the same therapy that induced remission 1

  • For 5-ASA-induced remission: continue rectal 5-ASA suppository daily (can reduce to every 2nd or 3rd day for adherence) 2
  • Never use corticosteroids for maintenance - they are ineffective and associated with significant adverse effects 1

Sexually Transmitted/Infectious Proctitis

When to Suspect

Proctitis occurring in patients with recent receptive anal intercourse, presenting with anorectal pain, tenesmus, and rectal discharge 10, 11

Diagnostic Approach

  • Perform anoscopy immediately 10
  • Evaluate for: N. gonorrhoeae, C. trachomatis (including LGV serovars), T. pallidum, and HSV 10, 11
  • Gram stain of anorectal secretions looking for polymorphonuclear leukocytes 10

Empiric Treatment (if anorectal pus or PMNs present)

Ceftriaxone 125 mg IM (or another agent effective against anal/genital gonorrhea) PLUS Doxycycline 100 mg orally twice daily for 7 days 10, 11

This covers both gonorrhea and chlamydia empirically while awaiting culture results.

Special Considerations

  • For herpes proctitis: Treat according to genital HSV protocols (this may be especially severe in HIV-coinfected patients) 10, 11
  • Proctocolitis (extending >12 cm with diarrhea/cramping): Consider Campylobacter, Shigella, Entamoeba histolytica, or LGV serovars of C. trachomatis 10
  • HIV-infected patients: CMV or other opportunistic infections may be involved 10

Critical Differentials to Exclude

Before committing to any treatment, rule out:

  • Infection (including sexually transmitted diseases)
  • Proximal constipation (can affect drug delivery in distal colitis)
  • Crohn's disease
  • Rectal prolapse/solitary rectal ulcer syndrome
  • Coexistent irritable bowel syndrome
  • Malignancy 2

Common pitfall: Poor adherence to rectal therapy is extremely common (5-ASA suppository monotherapy shows the worst compliance at 40% 8). Always assess adherence before escalating therapy. If adherence is an issue, consider switching formulations or reducing frequency rather than immediately escalating to systemic therapy.

References

Research

Management of refractory ulcerative proctitis.

Gastroenterologia y hepatologia, 2026

Research

Management of Patients with Ulcerative Proctitis: A Global Survey.

Digestive diseases and sciences, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.